Abstract
SUMMARYIntermittent claudication affects 5% of the middle‐aged population in developed countries and is associated with a significant reduction in health‐related quality of life and cardiovascular morbidity and mortality The mainstay of treatment is best medical therapy (BMT) comprising smoking cessation, antiplatelet agents, lipid‐lowering, advice to exercise, and correction of other modifiable vascular risk factors. Although BMT is highly effective in reducing cardiovascular risk and may also improve walking distance, many patients remain unacceptably symptomatic despite it. Until recently, the only available adjuvant therapies were supervised exercise programmes, angioplasty and surgery Many patients are unable to comply with the first, and the last two are associated with limited durability and risk. The advent of cilostazol (Pletal™) adds evidence‐based pharmacotherapy to the vascular specialist's armamentarium for the first time. Here cilostazol and its role in the management of intermittent claudication are discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
